Targeted Oncology12h
Orca-T Improves cGVHD-Free Survival Across Hematologic Malignancies
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...
Physician's Weekly17h
Hematological Effects of Radioiodine Therapy in Thyroid Cancer
The following is a summary of “Effect of radioactive iodine therapy on hematological parameters in patients with thyroid ...
Personalized cancer vaccine proves promising in a phase 1 trial
Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...
Medscape24d
Fatigue and Quality of Life Among Chinese Patients With Hematologic Malignancy After Bone Marrow Transplantation
A cross-sectional design was used to examine the intensity of fatigue in patients who underwent bone marrow transplantation for a hematologic malignancy, and to determine whether fatigue affected ...
Medical Dialogues23h
GLP-1 RA Use Linked to Lower Hematologic Cancer Risk in T2D Patients: JAMA
According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...
Medical Xpress8d
Risk for specific hematologic cancers down with GLP-1 receptor agonist use in type 2 diabetes
No significant difference was seen in the risk for any other hematologic cancer. GLP-1 RA use was associated with ...
The American Journal of Managed Care13d
Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
Panelists discuss how recent FDA approvals for bispecific antibodies in oncology, particularly for hematologic malignancies ...
Pacylex Pharmaceuticals Announces the First Acute Myeloid Leukemia (AML) Patient Dosed with Zelenirstat In a New Phase 1/2 Clinical Trial
Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company and world leader in developing N-myristoyltransferase inhibitors (NMTis) for cancer. Oral zelenirstat is under ...